Frontlight ResearchEarly access
Lung cancer trials in Spain
255 of 274 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in SpainAn international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.
- Where
- Granada, Madrid, Málaga, Murcia, Pamplona
- Age
- 18 years and over
- People
- 66 worldwide
- Run by
- Medica Scientia Innovation Research S.L.
See details and how to join2025-523824-39-01 - Phase 3Not yet taking people in SpainA Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
- Where
- A Coruña, Badajoz, Barcelona, Girona, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Sevilla, Valencia, Vigo, Zaragoza
- Age
- 18 years and over
- People
- 167 worldwide
- Run by
- Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 - Phase 1Taking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Barcelona, Castello De La Plana, L'Hospitalet de Llobregat, Madrid, Málaga, Pozuelo de Alarcón, Valencia
- Age
- 18 years and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- A Coruña, Badajoz, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Oviedo, Palma, Santander, Sevilla, Valencia, Valladolid
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 2Taking peopleSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Where
- Barcelona, L'Hospitalet de Llobregat, Pozuelo de Alarcón, Sevilla
- Age
- 18 years and over
- People
- 144 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00 - Phase 2/3Taking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Sevilla, Valencia
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - Phase 1/2Taking peopleA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Where
- Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga, Pamplona, Sevilla, Torrejón de Ardoz, Valencia
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07111520 · EU 2024-519344-32-00 - Phase 2Not yet taking people in SpainA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Where
- Barcelona, Logroño, Madrid
- Age
- 18 years and over
- People
- 105 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00 - Phase 1Active, not recruitingBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia
- Age
- 18 years and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00 - Phase 1/2Active, not recruitingFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia
- Age
- 18 years and over
- People
- 430 worldwide
- Run by
- Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00 - Phase 3Taking peopleImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
- Where
- Barcelona, Majadahonda, Valencia
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT05522660 - Phase 1Taking peopleA Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Logroño, Madrid
- Age
- 18 years and over
- People
- 124 worldwide
- Run by
- Pliant Therapeutics, Inc.
See details and how to joinNCT06270706 - Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Barcelona, Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Sevilla, Vic
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 3Taking peopleTrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Where
- A Coruña, Badalona, Barakaldo, Barcelona, Córdoba, Girona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Málaga, Marbella, Palma de Mallorca, Seville
- Age
- 18 years and over
- People
- 363 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT06472245 - Phase 3Taking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- A Coruna, Barcelona, Elche, Jerez de la Frontera, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Sevilla, Valencia
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - Phase 1/2Taking peopleA Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Where
- Barcelona, Logroño, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Valencia
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Bayer
See details and how to joinNCT06914128 · EU 2025-520623-24-00 - Phase 2/3Not yet taking people in SpainStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- A Coruña, Badalona, Barcelona, Madrid, Majadahonda, Sevilla, Valencia
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 2Taking peopleA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- Where
- Barcelona, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Sevilla
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07221474 · EU 2025-520902-37-00 - Phase 3Taking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pozuelo de Alarcón, Sevilla
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - Phase 3Taking peopleA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Where
- Barcelona, Girona, Madrid, Sevilla, Valencia
- Age
- 18 years and over
- People
- 310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00 - Phase 3Not yet taking people in SpainBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Where
- A Coruña, Badajoz, Barcelona, Las Palmas de Gran Canaria, Madrid
- Age
- 18 years and over
- People
- 550 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT07625644 - Phase 1/2Taking peopleDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- L'Hospitalet de Llobregat, Madrid, Valencia
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00 - Phase 4Taking peopleDabrafenib and/or Trametinib Rollover Study
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 3Taking peopleLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Barcelona, Elche, Lleida, Madrid, Málaga, Pamplona, Seville, Torrejón de Ardoz
- Age
- 18 years and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301